We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 21, 2021

18F-FDG-PET/CT and ctDNA Detection Identify Patients Unlikely to Respond to Exemestane–Everolimus

NPJ breast cancer


Additional Info

NPJ breast cancer
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
NPJ Breast Cancer 2021 Sep 21;[EPub Ahead of Print], A Gombos, D Venet, L Ameye, P Vuylsteke, P Neven, V Richard, FP Duhoux, JF Laes, F Rothe, C Sotiriou, M Paesmans, A Awada, T Guiot, P Flamen, M Piccart-Gebhart, M Ignatiadis, G Gebhart

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading